Drug Profile
Cetuximab sarotalocan - Rakuten Medical
Alternative Names: Akalux; ASP-1929; Cetuximab-IR700; RM-1929Latest Information Update: 31 Jan 2024
Price :
$50
*
At a glance
- Originator Aspyrian Therapeutics
- Developer National Cancer Center Hospital East; Rakuten Medical
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Cell death stimulants; Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Head and neck cancer
- Phase I/II Squamous cell cancer
- Phase I Oesophageal cancer
- Preclinical Cancer
- No development reported Gastric cancer
Most Recent Events
- 22 Jan 2024 Phase-III clinical trials in Head and neck cancer (Inoperable/Unresectable, Late-stage disease, Recurrent, Second-line therapy or greater) in India (IV) (NCT03769506)
- 10 Aug 2023 Rakuten Medical and Hikma Pharmaceuticals enters into a marketing agreement to commercialize in Middle East and North Africa
- 10 Jul 2023 Efficacy and adverse events data from phase I/II trials in Squamous cell cancer released by Rakuten Medical